Europe Puts Its API Dependence On Asia Under The Microscope
Europe and Asia’s Manufacturing Role Reversal Over 20 Years Is Analyzed
Executive Summary
The high concentration of API manufacturers in India and China posing a risk to the European supply chain became the highlight of the discussion among panellists at a recent Medicines for Europe webinar, as possible solutions to reduce the risk of shortages were pitched.
You may also be interested in...
EU Pharma Strategy Will Remove Barriers And Bolster Competition
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Biosimilar Education And Innovation Bills Head To Biden’s Desk
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Aurobindo’s Latest Launches Include Truvada And Atripla Rivals
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.